Investigational T-cell–redirecting biologic targeting human kallikrein-2 (KLK2) to direct T cells to lyse KLK2-expressing tumor cells.
Humanized IgG1 bispecific T-cell–redirecting antibody that binds KLK2 on tumor cells and CD3 on T cells, crosslinking them to activate and redirect T-cell cytotoxicity, resulting in lysis of KLK2-expressing tumor cells (notably in prostate cancer).
Bispecific T‑cell–redirecting antibody binds KLK2 on tumor cells and CD3 on T cells, forming a cytolytic synapse and activating T cells to kill KLK2+ cells via perforin/granzyme-mediated lysis.
HER2-targeted antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody linked via a cleavable linker to an exatecan-derived topoisomerase I inhibitor; after HER2 binding and internalization, the payload is released to induce Topo I–mediated DNA damage, S-phase arrest, apoptosis, and a bystander effect.
HER2-targeted antibody–drug conjugate linking a humanized anti‑HER2 monoclonal antibody via a cleavable linker to an exatecan-derived topoisomerase I inhibitor; after HER2 binding and internalization, the linker is cleaved to release the payload, which inhibits Topo I to induce DNA damage, S‑phase arrest, apoptosis, and a bystander cytotoxic effect.
The ADC binds HER2 on target cells, is internalized, and releases an exatecan-derived topoisomerase I inhibitor via a cleavable linker, causing DNA damage, S-phase arrest, and apoptosis (with potential bystander killing).
CD19-directed antibody–drug conjugate (ADCT-402) that delivers a pyrrolobenzodiazepine (PBD) dimer payload to crosslink DNA and induce cell death.
Humanized anti‑CD19 monoclonal antibody linked via a cleavable valine‑alanine linker to a pyrrolobenzodiazepine (PBD) dimer. After binding CD19 and internalization, the linker is cleaved to release the PBD payload, which binds the DNA minor groove at N2‑guanine positions to form interstrand crosslinks, blocking DNA replication and inducing cell death in CD19‑expressing B‑cell malignancies.
Anti-CD19 ADC binds CD19, is internalized, and releases a PBD dimer that forms DNA interstrand crosslinks, blocking replication and causing cell death in CD19+ cells.
Anti-CD20 monoclonal antibody that induces ADCC, CDC, and direct apoptosis of CD20-positive B cells.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and induces cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis, depleting CD20-positive B lymphocytes.
Binds CD20 on B cells and eliminates them via Fc-mediated ADCC (engaging NK cells/macrophages), complement-dependent cytotoxicity, and direct apoptotic signaling.
Anti-CD20 monoclonal antibody that depletes CD20+ B cells, reducing ANCA production.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis, thereby reducing ANCA production.
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP, and can trigger apoptosis, leading to depletion of CD20+ cells.